Loargys® (pegzilarginase) approved in Great Britain for treatment of arginase 1 deficiency (ARG1-D)
Stockholm, 21, 2023: Immedica today announces that the Medicines & Healthcare products Regulatory Agency in the UK has granted marketing authorization of Loargys® (pegzilarginase) for the treatment of arginase 1 deficiency (ARG1-D), also known as hyperargininaemia, in adults, adolescents and children aged 2 years and older. Orphan Designation in Great Britain was also granted. Anders Edvell, CEO of Immedica commented “This has indeed been an exciting week for Immedica with the approval in the EU on December 15 and now this approval in Great Britain, being one of the major markets in